The system enables surgeons to visualise and remove cancerous tissue in real time during breast-conserving surgeries. Credit: Peakstock / Shutterstock.

Lumicell has announced the launch of LumiSystem for real-time cancer detection, making it commercially available in the US.

The system combines the FDA-approved Lumisight optical imaging agent and Lumicell direct visualisation system (DVS), enabling surgeons to visualise and remove cancerous tissue in real time during breast-conserving surgeries.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

It claims to offer immediate feedback, potentially reducing the need for additional surgical procedures. The system’s real-time capabilities aim to achieve more complete tumour resection and improve patient outcomes.

In the INSITE pivotal trial, the LumiSystem demonstrated an 84% diagnostic accuracy and ‘improved’ surgical results for 10% of subjects by detecting cancerous tissue that was previously undetected by surgeons and pathologists.

This advancement offers a more comprehensive solution for breast-conserving surgery.

The primary objective of lumpectomy surgery is to excise the tumour and a margin of healthy tissue to ensure ‘negative margins’.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

However, existing surgical tools do not directly assess residual cancer within the surgical cavity, leading to limitations in pathology margin assessment and potential false readings.

These limitations often result in a 19% chance of residual cancer in cases deemed to have negative margins, the company noted.

Consequently, up to 36% of lumpectomy subjects may require a second surgery to remove missed cancerous tissue. The LumiSystem aims to significantly reduce these instances.

Lumicell CEO Howard Hechler said: “With LumiSystem’s commercial launch, we empower surgeons with a groundbreaking tool that detects cancer where and when it matters most, inside the breast cavity and in real-time.

“This launch reflects Lumicell’s unwavering commitment to enhancing surgical outcomes for patients.”

Lumicell specialises in developing fluorescence-guided imaging solutions to identify cancerous tissue during surgery.

Medical Device Network Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Medical Device Network Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now